Results 231 to 240 of about 129,754 (292)

Corticosteroid-Resistant Secondary Immune Thrombocytopenia in Smoldering Multiple Myeloma Successfully Treated With Eltrombopag: A Case Report. [PDF]

Cureus
Tominaga R, Kobayashi H.
europepmc   +1 more source

ESM‐1 and GBP‐1 are associated with endothelial dysfunction: emerging biomarkers or key players in the pathophysiology of preeclampsia?

The Journal of Physiology, EarlyView.
Abstract figure legend Endothelial specific molecule‐1 (ESM‐1) and guanylate binding protein‐1 (GBP‐1) are proteins that are produced by activated/dysfunctional endothelial cells and are increased and decreased, respectively, during preeclampsia. It remains to be established whether ESM‐1 and GBP‐1 could potentially be included as biomarkers for the ...
Ines Pronk, Joost H. N. Schuitemaker, Marijke M. Faas, Alexandra M. Smink   +3 more
wiley   +1 more source

Immunomodulatory Mechanisms and Therapeutic Potential of Vitamin D in Immune Thrombocytopenia. [PDF]

J Immunol Res
Ma Y, Yao W, Lang H, Cheng Y, Ren R, Chen Y, Cheng S, Sun S, Guo Q, Chen S.   +9 more
europepmc   +1 more source

Adjunctive Therapeutic Plasma Exchange in Refractory Adult‐Onset Still's Disease Complicated by Secondary Macrophage Activation Syndrome: A Single‐Center Experience

Therapeutic Apheresis and Dialysis, Volume 30, Issue 3, Page 389-396, June 2026.
ABSTRACT Introduction Adult‐onset Still's disease (AOSD) complicated by macrophage activation syndrome (MAS) carries substantial mortality. The role of therapeutic plasma exchange (TPE) remains uncertain. Methods We retrospectively analyzed patients with AOSD‐MAS treated with TPE at a single‐center.
Masataka Ueda, Tomohiro Saito, Masahide Mizobuchi, Tomoki Shimomura, Saki Kawamori, Mitsuru Kawanishi, Natsuko Hattori, Jo Sugiyama, Satoshi Tsubata, Hanami Horiguchi, Kazuki Abe, Nao Iida, Yuki Kajio, Nao Oguro, Ryo Yanai, Hirokazu Honda   +15 more
wiley   +1 more source

Rilzabrutinib in immune thrombocytopenia: a targeted, patient-centered alternative to conventional therapies. [PDF]

Ann Med Surg (Lond)
Afridi H, Qazi K, Rizvi MA, Nasir R, Mahato RK.   +4 more
europepmc   +1 more source

Fixed‐Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis

American Journal of Hematology, Volume 101, Issue 5, Page 986-997, May 2026.
ABSTRACT Mosunetuzumab is approved as an intravenous (IV) formulation for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥ 2 prior therapies. A subcutaneous (SC) formulation, aiming to improve patient safety and convenience, has been developed.
Nancy L. Bartlett, Laurie H. Sehn, Sarit Assouline, Pratyush Giri, John Kuruvilla, Stephen J. Schuster, Sung‐Soo Yoon, Keith Fay, Georg Hess, Martin Dreyling, Norma C. Gutierrez, Eva Cybulski, Fidelis Sabalvaro, Elicia Penuel, Vanda Teodoro, Samuel Tracy, Denison Kuruvilla, Joseph Chen, Volker Wiebking, Michael C. Wei, L. Elizabeth Budde   +20 more
wiley   +1 more source

Evaluating rilzabrutinib in the treatment of immune thrombocytopenia. [PDF]

Immunotherapy
Kuter DJ, Ghanima W.
europepmc   +1 more source

Noonan Syndrome Spectrum Disorders Predispose to Systemic Lupus Erythematosus: Case Report and Critical Review of the Literature

American Journal of Medical Genetics Part A, Volume 200, Issue 5, Page 1091-1097, May 2026.
ABSTRACT RASopathies are clinically overlapping neurodevelopmental syndromes resulting from germline mutations in genes involved in the rat sarcoma/mitogen‐activated protein kinases (RAS/MAPK) pathway. Historically, RASopathies have been described by clinical phenotypes, such as Noonan syndrome and Neurofibromatosis type I.
Anastasia‐Vasiliki Madenidou, Gillian I. Rice, James O'Sullivan, Ben Parker, Ian N. Bruce, Emma Burkitt‐Wright, Tracy A. Briggs   +6 more
wiley   +1 more source

Cyclic Thrombocytopenia Misdiagnosed as Immune Thrombocytopenia (ITP): Diagnostic and Therapeutic Lessons. [PDF]

Cureus
Seeburun S, Lee E, Salameh S, Eltoukhy H.   +3 more
europepmc   +1 more source